KLRS - Total Utang marang Modal Kalaris Tx

Kalaris Therapeutics Inc (KLRS) is developing a biopharmaceutical environment for combating viruses and ophthalmic vectors. This chart illustrates a total debt-to-equity ratio of 0.02. Kalaris Therapeutics Inc (KLRS) focuses on creating gene therapies and KLR101 antibodies while remaining in a stage of intensive research and development. Meanwhile, the business relies on outsourcing production and trials, which spares the startup from excessive capital expenditures.

For the biotech Kalaris Therapeutics Inc (KLRS), which eliminates production capital expenditures, the asset leverage dynamics on GURU.Markets reflect the balance between external financing and equity. This ratio is calculated as total liabilities to equity, measuring the degree of financial leverage and determining the stability of the company's equity structure in the face of potential default risks.